Healthcare
Instil Bio, Inc.(TIL)
Live Price
Offline$7.92
-0.13% today
1Y Change
-72.71%
Window
Jun 20, 2025 โ Jun 17, 2026
- Market Cap
- $50.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +6.1%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 20, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Instil Bio, Inc. (TIL) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $7.92 and down 72.7% across the available one-year price window (Jun 20, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +6.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +6.1%, free cash flow +44.3% with operating margin 0.0% and ROIC -39.5%. Stock Foundry combines TIL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +6.1%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -1.0% | -1.0% | -1.5% |
2026 Mar 27, 2026 | +47.6% | +2.3% | +8.6% | +4.4% |
2025 Nov 13, 2025 | -0.5% | +3.7% | -13.9% | -22.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TIL
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TIL Max Drawdown
-79.34%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TIL and SPY.
Company Overview
Instil Bio, Inc.
NASDAQ Global Select
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
- Leadership
- Bronson Crouch
- IPO Date
- Mar 19, 2021
- Employees
- 14
- Street Address
- 3963 Maple Avenue
- Mailing
- Dallas, TX, 75219
- Region
- Dallas, TX, US
- Reporting Currency
- USD
- Investor Line
- 972 499 3350
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 0.5
Growth
- Revenue
- 0.0%
- EPS
- +6.1%
- Free Cash Flow
- +44.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -55.9%
- ROIC
- -39.5%
Balance Sheet
- Debt/Equity
- 0.75
- Current Ratio
- 39.53
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.